Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.
Elucidating Alzheimer disease pathophysiology
Study of subjects with rare inherited form of AD shows increased retinal capillary perfusion during the presymptomatic stage.
Subretinal gene therapy for neovascular AMD showing efficacy and safety
Novel option demonstrates stable to improved visual acuity and retinal thickness
From ETDRS to EviRed: Eyeing a new artificial intelligence-based algorithm
The development of a novel AI-based algorithm aims to improve risk prediction for diabetic eye disease.
Deep learning algorithm proving accurate for AMD classification
Results of a prospective trial show the tool is ready for clinical use and potential deployment for remote telemedical use.
Managing the challenge of cataract surgery in eyes with diabetic macular edema
Researchers advocate for intraoperative intravitreal steroid during cataract surgery in patients with DME.
Study explores mental health issues in patients with diabetic retinopathy
Rates of anxiety and depression increased but were not necessarily tied to disease severity
Considering ethnicity-related differences in macular thickness among diabetics
A retrospective study found that in both patients with type 2 diabetes and non-diabetics, average central macular thickness was lower in Asians than Caucasians. Why is this significant for clinicians?
AMD risk phenotypes targeted in direct-to-consumer genetic database
Intraoperative surgical methods hold key to AMD treatment
Researchers find that targeted subretinal delivery of stem cell derived RPE to geographic atrophy is feasible
Look for clues to simplify anterior uveitis diagnosis
Ongoing study evaluates sirolimus as therapeutic option for uveitis
Inhibition plays role in autoimmune-based inflammation; has unique mechanism of action
Biologics may offer systemic therapy option for uveitis
One biologic response modifier has indication for uveitis; several in development to gain FDA approval
Sustained-release corticosteroid expands armamentarium for uveitis
FA implant effective in lowering recurrence rates through available 6, 12 months of follow-up
Understanding etiology crucial for appropriate uveitic treatment
Decreasing burden of nAMD therapy
Investigators optimistic about sustained-release ranibizumab delivery based on phase II LADDER study
Real-world study of the fluocinolone acetonide implant show its benefits for treating DME
IL-6 inhibition shows promise as treatment for non-infectious uveitis
Data promising in uveitic macular edema pivotal trial
Novel local corticosteroid therapy shows positive efficacy signals, favorable safety profile says Rahul Khurana, MD.
Intestinal microbiome proposed as potential therapeutic target for AMD
Schepens Lecturer shares ideas for moving forward in AMD
Three pearls for uveitis diagnosis
Success in retinal detachment surgery depends on using the right strategies
2 Clarke Drive Cranbury, NJ 08512